7 function and may influence the mechanical properties of bone (27) . These profound effects on bone turnover may in part contribute to complications such as osteonecrosis of the jaw (ONJ). In the oncologic setting BPs have often been used on a monthly-schedule for long periods of time, leading to high cumulative exposures. Myeloma patients with ONJ have a gene and protein profiling consistent with suppression of both bone resorption and formation (28) .
Moreover, a recent retrospective analysis of 4000 BP-treated patients identified median dose and duration of treatment as significant risk factors for ONJ development (29) . The ASCO guidelines for the use of BPs in myeloma-related bone disease have been recently updated to address concerns about ONJ (30) and new clinical trials are underway to optimize BP administration schedule. The most likely mechanism of action of nitrogen-containing BPs is inhibition of farnesyl pyrophosphate synthase in the mevalonate pathway (32) . In addition to inhibition of signaling proteins, such as RAS-ERK (33), BP anti-tumor effects are mediated by downregulation of telomerase expression, induction of apoptosis and inhibition of cell proliferation (34, 35) . BPs may play an anti-tumor role also by modifying the tumor microenvironment via anti-OC, anti-angiogenic and immunomodulatory effects (36) . Interestingly, ZA in combination with IL-2 achieved a clinical response in prostate cancer patients (37, 38 Although monthly injections of denosumab 120 mg induced stable disease in a subset of patients, the small number of patients enrolled in the study did not allow any conclusions on the anti-tumor effect of denosumab in myeloma. In the setting of hormone refractory prostate cancer, an ongoing randomized trial is assessing denosumab (120 mg monthly) versus placebo on bone metastasisfree and overall survival (NCT00286091, table 1). Further studies in combination strategies or in a remission setting will be useful to clarify any anti-tumor effects.
OTHER BIOLOGICALLY-BASED NOVEL DRUGS

Novel targets to inhibit OC-mediated bone resorption
In addition to the RANKL/OPG ratio imbalance, cancer-induced OC activation is associated with secretion of several OAFs that represent important (65) . These studies will provide novel antiresorptive agents for use in the setting of bone metastasis.
Targeting OB function.
To date, attention has largely been focused on targeting the OC. However, osteolytic lesions in myeloma and breast cancer patients are associated with impaired OB function leading to an imbalanced OC/OB axis. Therefore, therapeutic strategies aiming at restoring OB differentiation are now being explored as well ( Figure 2 ).
DKK1 is a WNT inhibitor that binds and sequesters the WNT receptor subunit LRP5, therefore inhibiting WNT/β-catenin signaling. We have studied the anabolic effects of two clinical-grade DKK1 neutralizing antibodies, BHQ880
Research. However, in hormone-refractory prostate cancer the effects of atrasentan on disease progression are discordant (72) (73) (74) . Also in combination strategies with conventional chemotherapy agents such as docetaxel in prostate cancer and carboplatin/paclitaxel in lung cancer, atransentan did not add any benefits on overall or progression-free survival (75, 76) . In the setting of bone metastasis of prostate cancer, atransentan and ZA did not prove synergistic on markers of bone metabolism (77) . More extensive studies are required to assess the efficacy of endothelin inhibition strategies (NCT00554229) ( Table 3) . Another option to achieve OB inhibition is provided by radiopharmaceuticals, strontium-89 and samarium-153, that localize preferentially to areas of active bone formation. (78) Not only do they provide pain relief in patients with bone metastasis, but may also improve survival in combination with chemotherapy. (79) Although OC activation is a common pathogenic event in bone disease, OB activity determines the development of osteolytic or osteoblastic metastasis and, therefore, represents an important target. In order to treat bone disease and suppress tumor growth, future strategies will require a combination of antiresorptive and anabolic agents. To understand the role of bone-targeted agents, it is also critical that we take into account the role of anti-tumor strategies with effects on bone remodeling. For example, immunomodulatory drugs like lenalidomide and pomalidomide exert anti-OC effects (80, 81) . Bortezomib, a proteasome inhibitor, stimulates OB differentiation via upregulation of RUNX2 and inhibits OC development (82, 83) . Therefore, the effects of bone-targeted drugs should be assessed in the context of bone effects of these novel anti-tumor agents.
The stage is set to study therapeutic strategies not only to inhibit cancerrelated bone disease but also to target the dissemination of cancer cells to sanctuary sites in the bone. Greater understanding of bone biology will inform these strategies. Novel biomarkers and functional imaging modalities will facilitate future drug development.
Research. • Recurrence free survival and overall survival in each group.
• Assess whether zoledronate added to standard adjuvant therapy can decrease or even prevent bone loss.
• 
